Discovering a novel drug class targeting the epitranscriptomics machinery - Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting the epitranscriptomics machinery.
Location: United States, New York
Total raised: $54M
Investors 1
| Date | Name | Website |
| - | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.10.2018 | Series A | $54M | - |
Mentions in press and media 5
| Date | Title | Description |
| 10.10.2018 | Gotham Therapeutics Launches with $54 Million Series A | NEW YORK--(BUSINESS WIRE)--Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, debuted today with a $54 million Series A financing co-led by founding investor Versant Ventures, Forbio... |
| 10.10.2018 | Gotham Therapeutics Launches with $54M Series A | NEW YORK, NY, Biotechnology company developing a novel drug class targeting RNA-modifying proteins, debuted today with a $54 million Series A financing. >> Click here for more funding data on Gotham Therapeutics >> To export... |
| 10.10.2018 | RNA metabolism-focused Gotham Therapeutics launches with $54M Series A round | The company’s approach centers on the emerging field of epitranscriptomics, a field of study within RNA metabolism that has been the focus of Dr. Samie Jaffrey, a professor of pharmacology Weill Cornell Medicine and a member of the company’... |
| 10.10.2018 | Gotham Therapeutics Raises $54M in Series A Funding | Gotham Therapeutics, a NYC-based biotechnology company developing a novel drug class targeting RNA-modifying proteins, raised $54m in Series A financing. The round was co-led by founding investor Versant Ventures, Forbion and S.R. One, with... |
| - | RNA metabolism-focused Gotham Therapeutics launches with $54M Series A round | A company developing a class of RNA-modifying proteins to potentially treat cancers, autoimmune disorders and neurodegenerative diseases has launched with a pool of cash from several investors. New York-based Gotham Therapeutics launched We... |